Occam Places Biotech Leader David Southwell as Chairman of Revolo Biotherapeutics
In January 2024, Occam recruited serial biotech CEO David Southwell as Chairman of Revolo Biotherapeutics, a Morningside investment with a novel platform addressing autoimmune disorders.
David is an experienced financial executive who earlier in his career worked in numerous private and public companies and executed multiple IPOs. He subsequently migrated to operational leadership roles with small biotechs and larger commercial-stage companies.
Most recently, David served as CEO of TScan Therapeutics, Inc. (NASDAQ: TCRX), a clinical-stage immuno-oncology company focused on T cell receptors. Prior to that, he was the CEO of Inotek Pharmaceuticals (NASDAQ: ITEK), a clinical-stage ophthalmology company that merged with Rocket Pharmaceuticals in 2018. David also served as the EVP and CFO of Human Genome Sciences until that company was acquired by GSK in 2012, and then as EVP and CFO of Sepracor. His career began in investment banking at Lehman Brothers Inc.
Occam Global is an international life science executive search and leadership advisory firm dedicated to building management teams for innovative companies in the biotech, techbio, life sciences, and venture capital sectors. Our firm’s unique strength lies in our seamless access to elite talent, proven expertise in aligning exceptional business and scientific leaders with optimal opportunities, and a steadfast dedication to creating meaningful industry impact, guided by elevated ethics and enlightened aggression. Trusted by entrepreneurs, investors, and corporations worldwide, Occam Global is recognized as the premier partner for executive search and recruitment in the life sciences. Our success is rooted in establishing trust, cultivating and valuing relationships, and committing to serve as forthright and good-humored partners in realizing extraordinary ambitions.